New Delhi, Nov 5 (PTI) Pharma packaging firm Schott Kaisha on Thursday said it is investing Rs 105 crore in its existing facilities to increase vial production by 30 crore pieces.

The decision comes at a time when drug manufacturers around the world are undertaking COVID-19 vaccine trials.

Also Read | Huawei Nova 8 SE, Nova 8 SE High Edition Launched; Check Prices, Features, Variants & Specifications.

Such complex medications are stored in Type 1 glass vials, which are produced at the company's facilities in Gujarat and Daman, Schott Kaisha said in a statement.

The company plans to complete the production ramp-up within a record time of 12 months, it added.

Also Read | Andy Dwyer From Parks and Rec Studied at Gopi Bahu’s School of Washing Laptops – Here’s Video Proof.

"Pharma companies all around the world are working relentlessly to find an effective vaccine for COVID-19. As a front-runner in the pharma packaging segment, we are committed to support the vaccine developers with the best packaging solutions," Schott Kaisha Director Rishad Dadachanji said.

The company is closely working with all its clients to supply them with vials and syringes for their vaccine trials and is continuously assessing their requirements to stay ahead of the curve, he added.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)